Standard BioTools Inc. Common Stock
LABStock
$0.86−31.01%52W
Market Cap$329.49M
P/E—
Div yield—
Beta1.46
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-43.70%
Price vs S&P 500 (4W)0.61%
VGM Score39.43
Market Capitalization$329.49M
Earnings Surprise History
Q1 260.33est. -0.06
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.86
3.86
4.00
4.00
Industry Peers — Lab Analytical Instruments(24)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LABStandard BioTools Inc. Common Stock | A | F | D | $0.86 |
| AAgilent Technologies Inc. | C | C | B | $136.10 |
| WATWaters Corp | D | C | B | $378.19 |
| ILMNIllumina Inc | D | D | A | $190.25 |
| MTDMettler-Toledo International | D | C | C | $1335.09 |
| RVTYRevvity, Inc. | C | D | B | $111.70 |
| BRKRBruker Corporation | D | D | B | $59.25 |
| BIOBio-Rad Laboratories, Inc.Class A | C | F | B | $300.98 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | F | B | $309.37 |
| AVTRAvantor, Inc. | B | F | B | $11.26 |
| TXG10x Genomics, Inc. Class A Common Stock | F | C | A | $44.48 |
About
Standard BioTools develops and manufactures advanced analytical instruments for biomedical research, primarily using mass cytometry and microfluidics technologies to accelerate drug discovery. The company operates two core segments—Proteomics and Genomics—with Proteomics representing the largest revenue contributor. Its solutions enable researchers to gain deeper insights into health and disease mechanisms, supporting faster therapeutic development. The company generates the majority of its revenue from the Americas.